Printer Friendly

ISIS PHARMACEUTICALS REPORTS SECOND QUARTER RESULTS

 ISIS PHARMACEUTICALS REPORTS SECOND QUARTER RESULTS
 CARLSBAD, Calif., July 31 /PRNewswire/ -- Isis Pharmaceuticals, Inc.


(NASDAQ: ISIP) today announced its financial results for the quarter ended June 30, 1992. Total revenues for the quarter, which consisted of contract research revenues and interest income, were approximately $3.8 million, compared to approximately $1.8 million for the second quarter of 1991, an increase of 28 percent. Operating expenses for the quarter were approximately $6.6 million, up 74 percent from approximately $2.8 million for the same quarter in 1991. The company recorded a net loss of approximately $4.3 million, or $.33 per share for the quarter, versus approximately $2.0 million, or $.21 per share for the comparable period in 1991.
 The increased operating expenses are a result of increased activity in research and development, including facilities and personnel additions to support the company's current and anticipated development activities.
 "The initial Phase I clinical trial for ISIS-2105, the company's compound to treat human papillomavirus, were completed in the second quarter," said Daniel Kisner, senior vice president, "we are continuing with another Phase I trial in patients with genital warts."
 Isis also consummated a cooperative research and development agreement with the Chemo-Sero-Therapeutic Research Institute (Kaketsuken) and Mochida Pharmaceutical Co., two significant Japanese pharmaceutical companies, to discover and develop human therapeutic products for Hepatitis C. "This agreement broadens Isis' base of molecular targets and provides an environment in which Isis and these Japanese pharmaceutical companies can take advantage of each others technology, skills and market presence," said B. Lynne Parshall, vice president.
 Isis Pharmaceuticals, Inc., based in northern San Diego County, is engaged in the discovery and development of novel therapeutic products based on antisense oligonucleotides. Isis recently completed its initial Phase I human clinical trails on a new drug, the first antisense drug to be administered to humans, to treat human papillomavirus.
 ISIS PHARMACEUTICALS
 Selected Financial Data
 (in thousands except loss per share)
 Statements of Operations
 Three months Six months
 Period ended June 30 1992 1991 1992 1991
 Revenues $2,303 $1,788 $4,796 $3,495
 Net loss (4,263) (2,015) (9,269) (3,116)
 Loss per share (.33) (.21) (.72) (.35)
 Weighted avg. shares
 outstanding 12,870 9,564 12,859 8,911
 Balance Sheets
 Periods ended 6/30/92 12/31/91
 Cash, cash equivalents &
 short-term investments $47,993 $60,998
 Total assets 65,006 73,625
 Long-term obligations,
 net of current portion 6,728 5,016
 Stockholders' equity 49,927 59,104
 -0- 7/31/92
 /CONTACT: B. Lynne Parshall of Isis Pharmaceuticals, 619-931-9200; or Anthony J. Russo of Noonan/Russo Communications, 212-979-9180, for Isis Pharmaceuticals/
 (ISIP) CO: Isis Pharmaceuticals Inc. ST: California IN: MTC SU: ERN


SH-LR -- NY009 -- 5485 07/31/92 10:03 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 31, 1992
Words:460
Previous Article:MCI PETITIONS MICHIGAN PUBLIC SERVICE COMMISSION TO INSTITUTE MORE LONG DISTANCE COMPETITION IN MICHIGAN
Next Article:MCN CORPORATION REPORTS HIGHER SECOND-QUARTER RESULTS
Topics:


Related Articles
ISIS PHARMACEUTICALS REPORTS THIRD QUARTER EARNINGS
ISIS PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR END RESULTS
ISIS PHARMACEUTICALS, INC. REPORTS LOWER LOSSES THAN EXPECTED WHILE CONTINUING THE PACE OF CLINICAL DEVELOPMENT
/C O R R E C T I O N -- ISIS PHARMACEUTICALS INC./
ISIS REPORTS CONTINUING TREND OF LOWER LOSSES FOR THE THIRD QUARTER OF 1993
ISIS PHARMACEUTICALS REPORTS SECOND QUARTER 1995 RESULTS
ISIS PHARMACEUTICALS REPORTS SECOND QUARTER 1996 RESULTS
Isis Pharmaceuticals Reports Third Quarter 1996 Results
Isis Pharmaceuticals Reports First Quarter 1997 Results
Isis Pharmaceuticals Reports Second Quarter 1997 Results

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters